Compare Abercrombie & Fitch Co. (ANF) vs Pfizer Inc (PFE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abercrombie & Fitch Co. vs Pfizer Inc — how do they compare? Abercrombie & Fitch Co. trades at $92.43 (market cap $4.14B), while Pfizer Inc trades at $24.24 (market cap $137.76B). The key difference: Pfizer Inc is far larger — about 33.3× Abercrombie & Fitch Co.'s market cap, and Pfizer Inc pays a 7.12% dividend while Abercrombie & Fitch Co. pays none. Which is the better fit depends on your goals.
| ANF | PFE | |
|---|---|---|
Market Cap | $4.14B | $137.76B |
Sector | Consumer Cyclical | Health |
52-Week High | $129.85 | $28.56 |
52-Week Low | $65.61 | $23.29 |
Enterprise Value | $4.81B | $188.41B |
Volume | — | 29,869,932 |
Dividend Yield | — | 7.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abercrombie & Fitch (ANF) trades at $93.07, up 4.29% with strong fundamental metrics including a P/E of 9 and net income margin of 9.34%. The stock shows consistent earnings beats in recent quarters and maintains robust profitability with ROE at 39.04%. Technical indicators are neutral overall, with bullish moving averages and key resistance at $94. Recent expansion initiatives include APAC growth opportunities and partnerships with Target for back-to-college merchandise.
ANF presents a compelling value opportunity with attractive valuation multiples and strong operational performance. Upside potential exists to the $107.71 consensus price target, though risks include moderating sales growth and international market volatility. The company's disciplined expansion and brand revitalization support long-term growth prospects.
Pfizer (PFE) trades at $24.17, down 0.33% on the day, with a bearish technical signal and neutral oscillators. The company maintains solid fundamentals with a P/E of 18.45, net income margin of 11.83%, and consistent quarterly earnings beats. Recent news highlights pipeline developments in obesity and oncology, with a $0.43 quarterly dividend providing income stability.
The outlook remains mixed: analyst consensus targets $27.63 (14% upside) but technicals suggest near-term pressure. Key risks include patent cliffs and competitive threats, while institutional sentiment leans hold. Valuation appears reasonable relative to cash flow generation, making PFE a defensive play with moderate growth potential amid ongoing pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
